President, Chief Executive Officer and Director
Mark A. Goldsmith, M.D., Ph.D. has served as a member of our board of directors and as our President and Chief Executive Officer since November 2014. Since 2009, Dr. Goldsmith has served as a member of the board of directors of Constellation Pharmaceuticals, Inc., a biopharmaceutical company, where he also served as President and Chief Executive Officer from 2009 to 2012, as Chairman from 2012 to June 2016 and from March 2017 to present, and as Interim Executive Chairman from June 2016 to March 2017. Dr. Goldsmith was previously a Partner with Third Rock Ventures, a life sciences venture capital firm, from 2013 to 2015, and a Venture Partner with Third Rock from 2012 to 2013. Dr. Goldsmith served as President and Chief Executive Officer and as a member of the board of directors of Global Blood Therapeutics, a biopharmaceutical company, from 2012 to 2014. Dr. Goldsmith also served as President and Chief Executive Officer of Nurix, Inc., a drug discovery company, from 2012 to 2014. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. Dr. Goldsmith received an A.B. from Princeton University in Biology and an M.D. and Ph.D. in Microbiology and Immunology from the School of Medicine of the University of California, San Francisco.
What is Mark A. Goldsmith's net worth?
The estimated net worth of Mark A. Goldsmith is at least $16.29 million as of April 10th, 2024. Dr. Goldsmith owns 452,879 shares of Revolution Medicines stock worth more than $16,285,529 as of April 28th. This net worth estimate does not reflect any other assets that Dr. Goldsmith may own. Additionally, Dr. Goldsmith receives a salary of $1,050,000.00 as Insider at Revolution Medicines. Learn More about Mark A. Goldsmith's net worth.
How old is Mark A. Goldsmith?
What is Mark A. Goldsmith's salary?
How do I contact Mark A. Goldsmith?
Has Mark A. Goldsmith been buying or selling shares of Revolution Medicines?
Within the last three months, Mark A. Goldsmith has sold $266,100.00 in shares of Revolution Medicines stock. Most recently, Mark A. Goldsmith sold 7,500 shares of the business's stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $35.48, for a transaction totalling $266,100.00. Following the completion of the sale, the insider now directly owns 452,879 shares of the company's stock, valued at $16,068,146.92. Learn More on Mark A. Goldsmith's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, insiders at the sold shares 34 times. They sold a total of 236,176 shares worth more than $7,455,013.90. The most recent insider tranaction occured on April, 10th when Director Sushil Patel sold 2,155 shares worth more than $79,735.00. Insiders at Revolution Medicines own 8.5% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 4/10/2024.
